Prescient Therapeutics (PTX) has signed a deal with Thermo Fisher Scientific to accelerate the development of its OmniCar platform.
Under the agreement, a development will be constructed to evaluate the potential of using automated, closed cell therapy solutions to develop a novel process of manufacturing cell therapies on the OmniCAR platform using non-viral methods.
The work program will develop the next generation OmniCAR cells that can be produced with greater efficiency, lower costs, and unmatched reproducibility.
Prescient’s focus will remain on creating OmniCAR cells with Thermo Fisher’s portfolio of proprietary equipment, and specialised cell and gene therapy manufacturing expertise.
Prescient Managing Director and CEO Steven Yatomi-Clarke said the company is delighted to enter this agreement with Thermo Fisher to accelerate the development of its OmniCAR platform.
“Whilst Prescient elected to develop its first internal OmniCAR programs using the validated approach of lentiviral transduction, we always have an eye on the future for any emerging advantages that can be incorporated into our programs whilst mitigating development risk,” Mr Yatomi-Clarke said.
“We are optimistic that this agreement with Thermo Fisher will accelerate the development of the OmniCAR platform to the point where one or more of Prescient’s internal OmniCAR programs can incorporate the advancements this agreement produces.
“Importantly, the agreement should result in an improved product and process that can be decentralised and therefore scaled with high efficiency and reproducibility.”
Prescient Therapeutics was up 2.86 per cent, trading at 18 cents at 12:01 pm AEST.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。